Short-term adverse effects of anticancer drugs in patients with type 2 diabetes. (3rd April 2019)

• Record Type: Journal Article
• Authors: Milluzzo, Agostino; Tumminia, Andrea; Vella, Veronica; Gianì, Fiorenza; Manzella, Livia; Frittitta, Lucia; Belfiore, Antonino; Vigneri, Riccardo; Sciacca, Laura
• Is Part Of: Journal of chemotherapy. Volume 31:Number 3(2019)
• Page Start: 150
• Page End: 159
• Publication Date: 2019-04-03
• Subjects: Cancer -- Anticancer treatment -- Diabetes -- Diabetes and Cancer -- Metabolic control -- Chronic complications; Chemotherapy -- Periodicals; Drug Therapy -- Periodicals; 615.58
• DOI: 10.1080/1120009X.2019.1572297
• Languages: English
• ISSNs: 1120-009X

Abstract

Abstract : The short-term adverse effects of anticancer drugs (AD) in patients with type 2 diabetes (T2D) are poorly studied and their management still represents an important challenge for clinicians. We carried out a retrospective single-center study in 168 patients with T2D and cancer, evaluating both the short-term effects of first-line AD on glycemic control and chronic diabetes complications. Average glycated hemoglobin significantly increased after AD compared to values before treatment (7.5 vs. 7.1%, p < 0.005). In 46.4% of patients, diabetes therapy had to be potentiated, in most cases (82.1%) by shifting to insulin. The use of alkylating agents and high-dose glucocorticoids predicted the need to potentiate diabetes therapy. After AD transaminase values significantly increased, whereas the estimated glomerular filtration rate decreased (in 12.5% <60 mL/min). Kinase inhibitors significantly increased the risk of microalbuminuria onset or progression. The present study provides a real-life information on the effects of different AD on the management of patients with T2D affected by several types of cancer.